Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY A HENDIN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1447239231
CMS profile
201693
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$334,177.38

468 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 10; records 151–200 of 468 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY A HENDIN

NPI 1447239231 · CMS profile ID 201693

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 10; records 151–200 of 468 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447239231?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 468 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447239231?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 468 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447239231?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 10; records 151–200 of 468 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447239231?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

468 matching records · $334,177.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 468 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 468.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Banner Life Sciences, LLC $8.2209/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957722179 CMS
Teva Pharmaceuticals USA, Inc. $19.6909/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954683973 CMS
Biogen, Inc. $1,839.0009/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923389309 CMS
E.R. Squibb & Sons, L.L.C. $116.3109/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732239 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0009/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732053 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0009/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732201 CMS
E.R. Squibb & Sons, L.L.C. $121.8209/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732205 CMS
Horizon Therapeutics plc $11.2409/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937632673 CMS
Biogen, Inc. $11.1809/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923442167 CMS
Horizon Therapeutics plc $18.4209/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937632671 CMS
Janssen Pharmaceuticals, Inc $18.1409/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885705509 CMS
EMD Serono, Inc. $27.3509/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941564129 CMS
EMD Serono, Inc. $3,710.0009/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941563121 CMS
EMD Serono, Inc. $3,710.0009/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941563267 CMS
Novartis Pharmaceuticals Corporation $9.9909/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893740079 CMS
Genentech USA, Inc. $32.7409/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658447 CMS
Genentech USA, Inc. $4,800.0009/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658449 CMS
Genentech USA, Inc. $32.5509/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658477 CMS
Genentech USA, Inc. $3,000.0009/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658481 CMS
Genentech USA, Inc. $1,862.3509/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658607 CMS
Genentech USA, Inc. $263.3509/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658609 CMS
Genentech USA, Inc. $124.1209/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658619 CMS
Genentech USA, Inc. $4,800.0009/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658622 CMS
Teva Pharmaceuticals USA, Inc. $23.3709/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954683969 CMS
Acorda Therapeutics, Inc $23.1309/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920332577 CMS
Janssen Pharmaceuticals, Inc $12.3009/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885705515 CMS
Biogen, Inc. $22.3509/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923394747 CMS
Biogen, Inc. $3,678.0009/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923445423 CMS
Teva Pharmaceuticals USA, Inc. $16.2609/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954683779 CMS
EMD Serono, Inc. $274.0009/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559347 CMS
EMD Serono, Inc. $407.3309/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559373 CMS
EMD Serono, Inc. $274.0009/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559391 CMS
EMD Serono, Inc. $17.8909/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559395 CMS
EMD Serono, Inc. $843.7709/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559397 CMS
EMD Serono, Inc. $34.9909/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559641 CMS
GENZYME CORPORATION $26.2609/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938738785 CMS
Acorda Therapeutics, Inc $11.3309/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920332575 CMS
Biogen, Inc. $16.5309/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923458969 CMS
E.R. Squibb & Sons, L.L.C. $22.3809/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732199 CMS
ABBVIE INC. $10.5309/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892790105 CMS
Banner Life Sciences, LLC $16.1909/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957721817 CMS
E.R. Squibb & Sons, L.L.C. $124.3308/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732055 CMS
E.R. Squibb & Sons, L.L.C. $768.5808/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932732079 CMS
UCB, Inc. $23.8908/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908062514 CMS
EMD Serono, Inc. $16.5308/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941555865 CMS
Biogen, Inc. $18.9708/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923441457 CMS
Biogen, Inc. $3,065.0008/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923464253 CMS
Biogen, Inc. $23.4308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923422683 CMS
Novartis Pharmaceuticals Corporation $11.7008/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893740075 CMS
Genentech USA, Inc. $28.0008/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950764511 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $524,413.88 456
PY2020 $267,685.72 228
PY2021 $215,462.97 338
PY2022 $334,177.38 468
PY2023 $287,949.77 386
PY2024 $355,333.39 411
PY2025 $279,651.53 382

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,433.92 4
PY2025 Principal investigator $465,283.11 18
PY2024 Recipient $1,997.07 3
PY2024 Principal investigator $119,785.94 4
PY2023 Recipient $21,685.00 1
PY2023 Principal investigator $572,937.80 16
PY2022 Recipient $10,861.00 5
PY2022 Principal investigator $381,064.86 11
PY2021 Recipient $2,451.00 1
PY2021 Principal investigator $334,583.62 39
PY2020 Recipient $7,508.96 3
PY2020 Principal investigator $47,007.77 20
PY2019 Principal investigator $168,349.27 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Novartis Pharmaceuticals Corporation $783.52 11/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291733
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,395.16 10/08/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311285
Principal investigator 1 Novartis Pharmaceuticals Corporation $878.52 10/06/2025 Non-covered Recipient Entity
PERSEVERANCE RESEARCH CENTER LLC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190312943
Principal investigator 1 Novartis Pharmaceuticals Corporation $270.00 10/01/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190311289
Principal investigator 1 Novartis Pharmaceuticals Corporation $453.00 10/01/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190311291
Principal investigator 1 Celgene Corporation $4,500.00 09/26/2025 Non-covered Recipient Entity
Perseverance Research Center
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1222306353
Recipient Novartis Pharma AG $18.62 09/25/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109099
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117969
Principal investigator 1 EMD Serono, Inc. $1,700.00 09/22/2025 Non-covered Recipient Entity
Perseverance Research Center LLC
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118457
Principal investigator 1 Novartis Pharmaceuticals Corporation $423.00 09/01/2025 Non-covered Recipient Entity
PERSEVERANCE RESEARCH CENTER LLC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190312945
Recipient Novartis Pharmaceuticals Corporation $1,356.78 06/03/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292383
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,068.11 05/27/2025 Non-covered Recipient Entity
Perseverance Research Center
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235994716
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117965
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,327.80 04/30/2025 Non-covered Recipient Entity
Perseverance Research Center
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235994718
Principal investigator 1 EMD Serono, Inc. $580.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117977
Principal investigator 1 EMD Serono, Inc. $1,280.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117980
Principal investigator 1 EMD Serono, Inc. $410.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117973
Principal investigator 1 EMD Serono, Inc. $440.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117984
Recipient Novartis Pharma AG $2,275.00 03/18/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109101
Principal investigator 1 EMD Serono, Inc. $23,601.00 03/06/2025 Non-covered Recipient Entity
Perseverance Research Center LLC
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118459
Principal investigator 1 Novartis Pharmaceuticals Corporation $57,031.73 01/31/2025 Non-covered Recipient Entity
PHOENIX NEUROLOGICAL ASSOCIATES LTD
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190303209
Principal investigator 1 Novartis Pharmaceuticals Corporation $367,234.79 01/08/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311287